Comprehensive definition of human immunodominant CD8 antigens in tuberculosis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comprehensive definition of human immunodominant CD8 antigens in tuberculosis
Authors
Keywords
-
Journal
npj Vaccines
Volume 2, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-03-29
DOI
10.1038/s41541-017-0008-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antigens for CD4 and CD8 T Cells in Tuberculosis
- (2014) C. S. Lindestam Arlehamn et al. Cold Spring Harbor Perspectives in Medicine
- Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis
- (2014) Mᵃdel Mar Serra-Vidal et al. Frontiers in Microbiology
- Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
- (2013) Michele D Tameris et al. LANCET
- Human Mycobacterium tuberculosis CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library
- (2013) David M. Lewinsohn et al. PLoS One
- Mycobacterium tuberculosis Specific CD8+ T Cells Rapidly Decline with Antituberculosis Treatment
- (2013) Melissa R. Nyendak et al. PLoS One
- Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells
- (2013) D. Weiskopf et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis
- (2013) Swati Singh et al. VACCINE
- Memory T Cells in Latent Mycobacterium tuberculosis Infection Are Directed against Three Antigenic Islands and Largely Contained in a CXCR3+CCR6+ Th1 Subset
- (2013) Cecilia S. Lindestam Arlehamn et al. PLoS Pathogens
- HowMycobacterium tuberculosisgoes to sleep: the dormancy survival regulator DosR a decade later
- (2012) Calvin Boon et al. Future Microbiology
- Human thymic MR1-restricted MAIT cells are innate pathogen-reactive effectors that adapt following thymic egress
- (2012) M C Gold et al. Mucosal Immunology
- Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
- (2012) Tom H. M. Ottenhoff et al. PLoS Pathogens
- Escape from the Phagosome: The Explanation for MHC-I Processing of Mycobacterial Antigens?
- (2012) Melanie J. Harriff et al. Frontiers in Immunology
- CD8+T Cells Provide an Immunologic Signature of Tuberculosis in Young Children
- (2011) Christina Lancioni et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Mycobacterial PE/PPE Proteins at the Host-Pathogen Interface
- (2011) Samantha L. Sampson Clinical & Developmental Immunology
- Views of immunology: effector T cells
- (2011) Deborah A. Lewinsohn et al. IMMUNOLOGICAL REVIEWS
- Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals
- (2011) C. Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genome-Based In Silico Identification of New Mycobacterium tuberculosis Antigens Activating Polyfunctional CD8+ T Cells in Human Tuberculosis
- (2010) S. T. Tang et al. JOURNAL OF IMMUNOLOGY
- Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy?
- (2010) Samuel M. Behar et al. NATURE REVIEWS MICROBIOLOGY
- Cell-Mediated Immune Responses in Tuberculosis
- (2009) Andrea M. Cooper Annual Review of Immunology
- New Vaccines Against Tuberculosis
- (2009) Paul-Henri Lambert et al. CLINICS IN CHEST MEDICINE
- TB vaccines: current status and future perspectives
- (2009) Claus Aagaard et al. IMMUNOLOGY AND CELL BIOLOGY
- The Enduring Hypoxic Response of Mycobacterium tuberculosis
- (2008) Tige R. Rustad et al. PLoS One
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started